IRX4 and non-small cell lung carcinoma: Previous research has confirmed that the knockdown of IRX4 can suppress stem-like characteristics and resistance to gefitinib in non-small cell lung cancer cells (102), although the specific mechanisms of IRX4 in PCa remain unclear.